Novotech, a global clinical research company, has agreed to buy Agilex Biolabs, a well-known bioanalytical lab based in Adelaide, Australia. The lab was previously owned by a subsidiary of Healius. This deal will help Novotech strengthen its ability to conduct clinical research by adding Agilex’s expert bioanalytical services to its existing lab network across Asia. Dr. Anand Tharmaratnam, the CEO of Novotech, shared his excitement about the acquisition, stating, ‘Agilex Biolabs has an excellent reputation in science. This move will improve Novotech’s services in Australia by combining advanced bioanalytical science and research. We’re excited to welcome the Agilex team to our company.’ He also emphasized that this acquisition will support innovative and cutting-edge research. Paul Anderson, Managing Director and CEO of Healius Limited, added, ‘This sale gives Agilex Biolabs’ customers and employees the chance to join Novotech, a well-established global company that works with major biotechnology and pharmaceutical clients.’ He explained further, ‘The sale provides Agilex Biolabs’ customers and team members with the opportunity to become part of an established and global business in Novotech.’ The acquisition will allow Novotech to offer faster and more effective research and development (R&D) support to biotech and pharmaceutical companies in Australia, a country known for being one of the best places in the world for early-stage clinical trials. The deal is expected to close once all usual conditions, including regulatory approvals, are met. Novotech is a global company with over 30 offices in Asia-Pacific, North America, and Europe. They work with more than 5,000 trial sites and provide a full range of clinical development services for biotech and small to mid-sized pharmaceutical companies.